Based on these results and our previous work, we conclude that our approach has sufficient power to recover TCR and BCR CDR3s to evaluate the fraction and diversity of both T and B cells from bulk RNA-seq data, which allowed us to identify the changes of T and B cells between AML and non-tumor samples. This evidence concerns the gene BCR and neoplasm.